Certara (CERT) to Release Earnings on Thursday

Certara (NASDAQ:CERT) is projected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $103.2290 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Certara Stock Up 0.3%

Certara stock opened at $6.53 on Thursday. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27. Certara has a 1-year low of $6.44 and a 1-year high of $15.38. The firm’s fifty day simple moving average is $8.66 and its 200-day simple moving average is $10.07. The company has a market capitalization of $1.04 billion, a P/E ratio of 93.29 and a beta of 1.47.

Institutional Investors Weigh In On Certara

Institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after buying an additional 2,870 shares in the last quarter. Osaic Holdings Inc. grew its position in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the period. Tower Research Capital LLC TRC raised its stake in Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after acquiring an additional 4,930 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Certara during the second quarter valued at $83,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Certara in the 4th quarter valued at $92,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Morgan Stanley lowered their target price on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, December 18th. Rothschild & Co Redburn set a $10.00 price objective on shares of Certara in a research note on Friday, November 21st. Leerink Partners upgraded shares of Certara from a “market perform” rating to an “outperform” rating and set a $13.00 target price for the company in a research note on Tuesday, January 6th. Barclays reduced their price target on shares of Certara from $14.00 to $13.00 and set an “overweight” rating for the company in a report on Monday, December 15th. Finally, BMO Capital Markets began coverage on shares of Certara in a report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.82.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.